{"id":578,"date":"2020-02-17T13:11:07","date_gmt":"2020-02-17T12:11:07","guid":{"rendered":"https:\/\/www.sunrockbiopharma.com\/her3\/"},"modified":"2024-04-11T16:50:04","modified_gmt":"2024-04-11T14:50:04","slug":"her3","status":"publish","type":"page","link":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/","title":{"rendered":"HER3"},"content":{"rendered":"<p>[vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n<h2>Diana HER3<\/h2>\n<p>[\/vc_column_text][vc_column_text]Desde que se descubri\u00f3 que el Receptor del Factor de Crecimiento Epid\u00e9rmico (EGFR, HER1) se sobreexpresa en tumores humanos en 1984, los Receptores del Factor de Crecimiento Epid\u00e9rmico Humano han demostrado ser de suma importancia en la oncog\u00e9nesis y la regulaci\u00f3n de la progresi\u00f3n de muchos tipos de c\u00e1ncer as\u00ed como la aparici\u00f3n de resistencia contra el tratamiento y, por lo tanto, esta familia puede considerarse un grupo de potenciales dianas terap\u00e9uticas.<\/p>\n<p>La dimerizaci\u00f3n de HER conduce a la activaci\u00f3n alost\u00e9rica de su dominio de quinasa y posterior se\u00f1alizaci\u00f3n. Solo entre los HER, HER3 juega un papel clave en el desarrollo de resistencia a las terapias de bloqueo de EGFR y HER2<\/p>\n<p>HER3 es, por lo tanto, una pieza central de este sistema, dimerizando con HER2 \/ EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos. La complejidad del eje HER3-HER2, en el que intervienen muchos mecanismos de regulaci\u00f3n, lo hace bastante robusto.[\/vc_column_text][\/vc_column][\/vc_row][vc_row css_animation=\u00bbfadeIn\u00bb foundry_padding=\u00bbpt0 pb0&#8243;][vc_column css_animation=\u00bbfadeInLeft\u00bb][vc_column_text]<\/p>\n<h2>Anticuerpos Terap\u00e9uticos Anti-HER3<\/h2>\n<p>[\/vc_column_text][\/vc_column][vc_column css_animation=\u00bbfadeInUp\u00bb][vc_column_text]SunRock ha desarrollado una nueva IgG1 con afinidad mejorada (EC<sub>50<\/sub> picomolar) y un sitio de uni\u00f3n que mantiene a HER3 en una conformaci\u00f3n cerrada, interfiere con la uni\u00f3n de HER3 a HER2 \/ EGFR y evita la dimerizaci\u00f3n, por lo tanto, interrumpe la se\u00f1alizaci\u00f3n en ausencia de ligando. Esta nueva IgG ha dado resultados en xenoinjertos de c\u00e1ncer con valores de TGI de hasta el 80%.<\/p>\n<p>HER3 es una diana terap\u00e9utica bien conocida, asociada a la progresi\u00f3n del c\u00e1ncer, peor supervivencia y resistencia adquirida a los medicamentos dirigidos a HER2 y EGFR.<\/p>\n<p>La sobreexpresi\u00f3n de HER3 se ha descrito, entre otras indicaciones, en el c\u00e1ncer de mama amplificado con HER2 y en el c\u00e1ncer colorrectal metast\u00e1sico avanzado (mCRC).<\/p>\n<p>Adem\u00e1s, los anticuerpos biespec\u00edficos anti-HER3 \/ anti-EGFR est\u00e1n siendo desarrollados en diferentes formatos. Estos bsAbs superan el efecto antitumoral del est\u00e1ndar de tratamiento en diferentes indicaciones oncol\u00f3gicas.<\/p>\n<p>SunRock posee los derechos exclusivos de propiedad intelectual en todo el mundo que protegen nuestros anticuerpos dirigidos contra HER3.[\/vc_column_text][vc_tta_tour style=\u00bbflat\u00bb shape=\u00bbsquare\u00bb color=\u00bbwhite\u00bb active_section=\u00bb1&#8243; css_animation=\u00bbnone\u00bb el_class=\u00bbtour-anti\u00bb][vc_tta_section title=\u00bbSRB17&#8243; tab_id=\u00bb1581940981816-2f44340e-8bee\u00bb][vc_column_text]<\/p>\n<h3>SRB17<\/h3>\n<p>[\/vc_column_text][vc_column_text]SunRock, en colaboraci\u00f3n con la Universidad de Stuttgart (Alemania), ha desarrollado SRB17, una anti-HER3 IgG1 totalmente humana, la mejor en su clase, con una afinidad mejorada y un mecanismo de acci\u00f3n dual.<\/p>\n<p><strong>SRB17 muestra una afinidad mejorada en comparaci\u00f3n con otros anticuerpos anti-HER3 desarrollados por grandes\u00a0compa\u00f1\u00edas\u00a0farm\u00e1ceuticas.<\/strong><\/p>\n<ul>\n<li>El sitio de uni\u00f3n de SRB17 impide la activaci\u00f3n dependiente de ligando de HER3, y tambi\u00e9n la activaci\u00f3n alost\u00e9rica de HER2 de HER2 y EGFR (Schmitt <em>et al<\/em>. 2017).<\/li>\n<\/ul>\n<p><strong>SRB17 inhibe el crecimiento tumoral y aumenta significativamente la supervivencia media en un modelo de xenoinjerto subcut\u00e1neo de c\u00e1ncer de cabeza y cuello (FaDu) en ratones SCID.<\/strong>[\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00bbANTICUERPO BIFUNCIONAL HER3-TRAIL\u00bb tab_id=\u00bb1581941276769-32bd3ce6-2ac0&#8243;][vc_column_text]<\/p>\n<h3>ANTICUERPO BIFUNCIONAL HER3-TRAIL<\/h3>\n<p>[\/vc_column_text][vc_column_text]SunRock ha desarrollado SRB22, un nuevo anticuerpo bifuncional anti-HER3-TRAIL con un nuevo <em>linker<\/em> y una eficacia mejorada. Esta mol\u00e9cula muestra una eficacia antitumoral hasta 40 veces superior a TRAIL no dirigido. SRB22 desencadena la muerte espec\u00edfica de c\u00e9lulas tumorales mediante la inducci\u00f3n de apoptosis.<\/p>\n<p>SRB22 desencadena la muerte celular dentro del rango picomolar en diferentes modelos tumorales que incluyen c\u00e1ncer colorrectal, c\u00e1ncer g\u00e1strico, melanoma, etc.<\/p>\n<p><em>In vivo<\/em>, SRB22 logra una regresi\u00f3n tumoral completa hasta en un 90% en diferentes modelos de xenoinjertos resistentes a inmunoterapia.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=\u00bbSRB19&#8243; tab_id=\u00bb1581941350656-98e222d3-ee30&#8243;][vc_column_text]<\/p>\n<h3>SRB19<\/h3>\n<p>[\/vc_column_text][vc_column_text]SRB19 es una prote\u00edna de fusi\u00f3n Tetravalente de cadena simple Diabody-Fc, que inhibe la fosforilaci\u00f3n independiente y dependiente de ligandos de EGFR y HER3 en varios modelos tumorales superando la eficacia antitumoral del combo de anticuerpos individuales<\/p>\n<p><strong>El tratamiento con SRB19 supera el efecto del cetuximab<\/strong> en modelos de c\u00e1ncer <em>in vivo<\/em> de cabeza y cuello. SRB19 produjo un 90% de regresi\u00f3n tumoral y redujo la toxicidad hep\u00e1tica en modelos de xenoinjerto subcut\u00e1neo HNSCC.<\/p>\n<p>En los modelos ortot\u00f3picos TNBC, <strong>el tratamiento con SRB19 supera el efecto de la combinaci\u00f3n de los dos anticuerpos parentales que inhiben el tumor.<\/strong>[\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row][vc_row css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbfirst-section\u00bb][vc_column el_class=\u00bbbox-shadow\u00bb][vc_column_text]<\/p>\n<h2><span lang=\"EN-US\">Anti-HER3 Pipeline <\/span><\/h2>\n<p>[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00bb1\/6&#8243;][vc_empty_space height=\u00bb65px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_empty_space height=\u00bb20px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_column_text]<\/p>\n<h5>SRB22, anti-HER3-TRAIL bifuncional<\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/6&#8243;][vc_column_text]<strong>Descubrimiento<\/strong>[\/vc_column_text][vc_separator border_width=\u00bb4&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_empty_space height=\u00bb59px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text]<\/p>\n<p style=\"text-align: center;\"><strong>Precl\u00ednica<\/strong><\/p>\n<p>[\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_empty_space height=\u00bb59px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#45509a\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_empty_space height=\u00bb59px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#e0c03d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text]<strong style=\"white-space: nowrap;\">Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#e0c03d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom srb2-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_empty_space height=\u00bb59px\u00bb el_class=\u00bbhidden-xs hidden-sm\u00bb][vc_separator color=\u00bbcustom\u00bb border_width=\u00bb4&#8243; accent_color=\u00bb#e0c03d\u00bb][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00bbmiddle\u00bb][vc_column_inner width=\u00bb1\/6&#8243;][vc_column_text]<\/p>\n<h5>SRB17, anti-HER3 mAb<\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/6&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Descubrimiento<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Precl\u00ednica<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong style=\"white-space: nowrap;\">Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00bbmiddle\u00bb][vc_column_inner width=\u00bb1\/6&#8243;][vc_column_text]<\/p>\n<h5>SRB19, anti-HER3-EGFR biespec\u00edfico<\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/6&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Descubrimiento<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Precl\u00ednica<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong style=\"white-space: nowrap;\">Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][\/vc_row_inner][vc_row_inner content_placement=\u00bbmiddle\u00bb][vc_column_inner width=\u00bb1\/6&#8243;][vc_column_text]<\/p>\n<h5>SRB21, anti-HER3-HER2 biespec\u00edfico<\/h5>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/6&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Descubrimiento<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Descubrimiento%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong>Precl\u00ednica<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vitro%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22in%20vivo%22%2C%22value%22%3A%22100%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243; customtxtcolor=\u00bb#ffce1c\u00bb el_class=\u00bbem\u00bb][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Regulatoria%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_column_text el_class=\u00bbvisible-xs visible-sm\u00bb]<strong style=\"white-space: nowrap;\">Fases cl\u00ednicas<\/strong>[\/vc_column_text][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20I%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20II%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][vc_column_inner el_class=\u00bbcol-md-custom her-pipeline\u00bb width=\u00bb1\/12&#8243;][vc_progress_bar values=\u00bb%5B%7B%22label%22%3A%22Fase%20III%22%2C%22value%22%3A%220%22%7D%5D\u00bb bgcolor=\u00bbcustom\u00bb custombgcolor=\u00bb#070f26&#8243;][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column css_animation=\u00bbfadeInUp\u00bb el_class=\u00bbbox-shadow\u00bb][vc_column_text] Diana HER3 [\/vc_column_text][vc_column_text]Desde que se descubri\u00f3 que el Receptor del Factor de Crecimiento Epid\u00e9rmico (EGFR, HER1) se sobreexpresa&#8230;<\/p>\n","protected":false},"author":1,"featured_media":579,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_mi_skip_tracking":false,"footnotes":""},"class_list":["post-578","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v17.7.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\r\n<title>SunRock Biopharma | HER3<\/title>\r\n<meta name=\"description\" content=\"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.\" \/>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"SunRock Biopharma | HER3\" \/>\r\n<meta property=\"og:description\" content=\"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/\" \/>\r\n<meta property=\"og:site_name\" content=\"SunRock Biopharma\" \/>\r\n<meta property=\"article:modified_time\" content=\"2024-04-11T14:50:04+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\" \/>\r\n\t<meta property=\"og:image:width\" content=\"1201\" \/>\r\n\t<meta property=\"og:image:height\" content=\"631\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:title\" content=\"SunRock Biopharma | HER3\" \/>\r\n<meta name=\"twitter:description\" content=\"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.\" \/>\r\n<meta name=\"twitter:image\" content=\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-tw.png\" \/>\r\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#organization\",\"name\":\"SunRock Biopharma\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#logo\",\"inLanguage\":\"es\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"contentUrl\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"width\":1201,\"height\":631,\"caption\":\"SunRock Biopharma\"},\"image\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#website\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/\",\"name\":\"SunRock Biopharma\",\"description\":\"Solutions for cancer therapy\",\"publisher\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sunrockbiopharma.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#primaryimage\",\"inLanguage\":\"es\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"contentUrl\":\"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png\",\"width\":1201,\"height\":631,\"caption\":\"sunrock\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#webpage\",\"url\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/\",\"name\":\"SunRock Biopharma | HER3\",\"isPartOf\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#primaryimage\"},\"datePublished\":\"2020-02-17T12:11:07+00:00\",\"dateModified\":\"2024-04-11T14:50:04+00:00\",\"description\":\"HER3, dimerizado con HER2\/EFGR, dianas terap\\u00e9uticas en oncolog\\u00eda a los que com\\u00fanmente se presenta resistencia a los tratamientos.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sunrockbiopharma.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HER3\"}]}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SunRock Biopharma | HER3","description":"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/","og_locale":"es_ES","og_type":"article","og_title":"SunRock Biopharma | HER3","og_description":"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.","og_url":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/","og_site_name":"SunRock Biopharma","article_modified_time":"2024-04-11T14:50:04+00:00","og_image":[{"width":1201,"height":631,"url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"SunRock Biopharma | HER3","twitter_description":"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.","twitter_image":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-tw.png","twitter_misc":{"Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.sunrockbiopharma.com\/#organization","name":"SunRock Biopharma","url":"https:\/\/www.sunrockbiopharma.com\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"https:\/\/www.sunrockbiopharma.com\/#logo","inLanguage":"es","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","width":1201,"height":631,"caption":"SunRock Biopharma"},"image":{"@id":"https:\/\/www.sunrockbiopharma.com\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.sunrockbiopharma.com\/#website","url":"https:\/\/www.sunrockbiopharma.com\/","name":"SunRock Biopharma","description":"Solutions for cancer therapy","publisher":{"@id":"https:\/\/www.sunrockbiopharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sunrockbiopharma.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"ImageObject","@id":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#primaryimage","inLanguage":"es","url":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","contentUrl":"https:\/\/www.sunrockbiopharma.com\/wp-content\/uploads\/2020\/09\/sunrock-seo-fb.png","width":1201,"height":631,"caption":"sunrock"},{"@type":"WebPage","@id":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#webpage","url":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/","name":"SunRock Biopharma | HER3","isPartOf":{"@id":"https:\/\/www.sunrockbiopharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#primaryimage"},"datePublished":"2020-02-17T12:11:07+00:00","dateModified":"2024-04-11T14:50:04+00:00","description":"HER3, dimerizado con HER2\/EFGR, dianas terap\u00e9uticas en oncolog\u00eda a los que com\u00fanmente se presenta resistencia a los tratamientos.","breadcrumb":{"@id":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sunrockbiopharma.com\/es\/her3\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sunrockbiopharma.com\/es\/her3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sunrockbiopharma.com\/es\/"},{"@type":"ListItem","position":2,"name":"HER3"}]}]}},"_links":{"self":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/comments?post=578"}],"version-history":[{"count":22,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/578\/revisions"}],"predecessor-version":[{"id":1258,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/pages\/578\/revisions\/1258"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media\/579"}],"wp:attachment":[{"href":"https:\/\/www.sunrockbiopharma.com\/es\/wp-json\/wp\/v2\/media?parent=578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}